Khosla Ventures participated in Moonwalk Biosciences' $70M Series B round co-led by Alpha Wave Global and YK Bioventures, to advance siRNA obesity treatments toward clinical trials.
Moonwalk Biosciences is a genomic medicine company pioneering precision epigenetic medicines, focusing on developing first-in-class, adipose-targeted RNA therapies for cardiometabolic diseases
Moonwalk Biosciences is a genomic medicine company pioneering precision epigenetic medicines, focusing on developing first-in-class, adipose-targeted RNA therapies for cardiometabolic diseases. The company integrates AI-enabled discovery with deep human genetics and epigenetics to create novel therapies that address obesity and related conditions.